Association between physical performance and cardiovascular events in patients with coronary artery disease: protocol for a meta-analysis

Shuhei Yamamoto 1,2*, Takayoshi Yamaga 1, Yasunari Sakai 1, Takaaki Ishida 1, Saki Nakasone 1, Masayoshi Ohira 3, Erika Ota 2 and Rintaro Mori 2

Abstract

Background: Physical performance such as muscle strength or walking speed of patients with coronary artery disease (CAD) is lower than that of people who do not have CAD and is related to mortality and re-admission rates. Recent studies have shown that skeletal muscle strength, such as grip strength, was closely associated with cardiac events. Physical performance testing is quick, safe, and inexpensive and provides a reliable assessment tool for routine clinical practice. The aim of this meta-analysis is to clarify the association between physical performance testing and the risk of cardiovascular events and mortality.

Methods/design: This meta-analysis will include male and female participants of any age in community settings who have a history of the following conditions or procedures: myocardial infarction, or coronary revascularization (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, or coronary artery stent), angina pectoris, heart failure, heart transplant, or coronary artery disease defined by angiography. We will search EMBASE and MEDLINE, PubMed, and the Cochrane Library with no limitations on date, language, document type, or publication status. Identified studies will be prospective and retrospective cohort studies. Physical performance will be defined as upper extremity strength, lower extremity strength, walking speed, or other performance scale. Six review authors will independently extract study characteristics from included studies. Participants will be divided into subgroups according to age (middle-aged <65 years and elderly ≥65 years), diagnosis (coronary artery disease and heart failure) and follow-up time (up to 12 months and over 12 months). We will pool hazard ratios of Cox proportional hazard models after logarithmic transformation and perform the meta-analysis by using inverse-variance method.

Discussion: To our knowledge, this meta-analysis will be the first report to assess the association between physical performance and cardiovascular events in CAD patients. We hope that these findings may help to estimate the prognosis for CAD patients in clinical practice.

Systematic review registration: PROSPERO CRD42015020886.

Keywords: Coronary artery disease, Physical performance, Physical functions, Meta-analysis, Protocol, Secondary prevention
Background
As the life expectancy of patients with heart disease has improved in recent years [1], secondary prevention of re-admission and mortality of these patients is becoming an important issue. Previous studies have shown that circulating biomarkers (e.g., brain natriuretic peptide) [2] and cardiac functions obtained by echocardiography testing (e.g., left ventricular ejection fraction) [3, 4] affect the mortality of these patients. Additionally, recent studies have shown that decreased physical performance such as muscle strength or walking speed was closely related to mortality and cardiovascular events [5, 6]. That physical performance of patients with coronary artery disease (CAD) decreases to approximately 70% relative to that of people who do not have CAD [7] and is related to mortality and re-admission rates [8–10]. Our previous study showed that a decrease in the walking speed of CAD patients was a strong prognostic indicator of cardiovascular events [5]. Furthermore, deterioration in skeletal muscle strength such as grip strength [11] or leg strength [6, 12] was closely associated with cardiac events in CAD patients. Physical performance testing offers a fast, safe, affordable, and reliable tool for clinical practice. Therefore, further development of physical performance testing is needed. However, the relationship between physical performance testing and cardiovascular events differs by diagnosis and age. For this reason, it is necessary to divide patients into age groups (middle-aged and elderly) or diagnosis groups (CAD and heart failure) in order to verify the association between physical performance and cardiovascular events.

The aim of this meta-analysis is to clarify the association between physical performance testing and risk of cardiovascular events and mortality.

Methods/design
This meta-analysis was registered with PROSPERO (our registration number: CRD42015020886). We based the review methods on the guidelines of Meta-analysis of Observational Studies in Epidemiology (MOOSE) [13], Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) [14], and Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) statement [15].

Search methods for identification of studies
We will search EMBASE and MEDLINE via Ovid SP, PubMed, and the Cochrane Library via Wiley Online Library with no restrictions on date/time, language, document type, and publication status. Keywords will be collected through experts' opinion, literature review, controlled vocabulary (Medical Subject Headings = MeSH and Excerpta Medica Tree = EMTREE) and by reviewing the primary search results. Also, to retrieve cohort studies, we will use the search filter developed by the BMJ Evidence Centre. Search strategies developed with the assistance of a medical information specialist were reported in the Appendix. The process of study selection is shown in a PRISMA flow diagram (Fig. 1).

Inclusion and exclusion criteria
We will identify prospective and retrospective cohort studies. Physical performance will be defined as upper extremity strength (e.g., grip strength), lower extremity strength (e.g., isometric or isotonic knee extension), walking speed, or other performance scale (e.g., short physical performance battery). We will include male and female participants of any age in community settings who have a history of the following: myocardial infarction, or coronary revascularization (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, or coronary artery stent), angina pectoris, heart failure, heart transplant, or coronary artery disease defined by angiography. We will include studies that enrolled participants with these histories confirmed by the medical record or administrative data.

We will exclude from the analysis those participants who have dementia, low vision or blindness, orthopedic surgery (e.g., hip or knee replacement and spinal surgery), and paralysis due to stroke. If such histories are not available in the paper, we will contact the authors of the study to obtain the missing information.

Type of main outcomes
1. Mortality due to all cause
2. Mortality due to cardiovascular event
3. Re-hospitalization due to cardiovascular event

Data extraction and management
We will use a data extraction form for the study information and outcome data. Six review authors (SY, TY, SN, TI, YS, and MO) will be divided into three teams (SY and TY, SN and TI, and YS and MO). They will independently extract study information from the included studies, as follows:

1. Methods: study design, study setting, duration of follow-up, and statistical analysis
2. Subjects: sample size, mean age, sex, history of stroke, history of orthopedics, and history of cancer
3. Outcome measures: physical performance test, concomitant medications, and excluded medications
4. Outcomes: main outcomes specified and collected and time points reported
5. Notes: funding for trial and notable conflicts of interest of trial authors
If the authors disagree with each other in the teams, we will resolve disagreements by discussion or by involving a third person (EO). One review author (SY) will transfer data from a data extraction form to the Review Manager file. We will double-check whether the data is entered correctly by comparing the presented data in the systematic review and research reports data. A second review author (RM) will randomly check the extracted data and characteristics against the source in order to ensure accuracy.

Assessment of risk of bias

Two review authors (SY and TY) will independently evaluate the risk of bias for each study according to the Risk of Bias Assessment Tool: for Non-Randomized Studies (RoBANS) [16]. We will resolve any disagreements by discussion or by involving other authors (EO and RM). We will evaluate the risk of bias assessment tool, as follows:

1. Selection of participants
2. Confounding variables
3. Measurement of exposure
4. Blinding of outcome assessments
5. Incomplete outcome data
6. Selective outcome reporting

We will assess each domain as high, low, or unclear risk of bias and determine our judgements using criteria from the Cochrane Handbook [17].

Data synthesis and analysis

We will perform the meta-analysis independently by each physical performance scale (e.g., upper extremity strength or lower extremity strength). Participants will be divided into subgroups according to age (middle-aged < 65 years and elderly ≥ 65 years), diagnosis (CAD and heart failure), and follow-up time (up to 12 months and over 12 months). Data synthesis and analyses will be performed using Review Manager version 5.3. We will perform a meta-analysis using the hazard ratios after logarithmic transformation by using inverse-variance method. Furthermore, we will synthesize the hazard ratios adjusted by variables of age and sex at least because the physical performance scales are closely affected by that factors. If we are able to pool more than 10 trials,
we will create and examine funnel plot asymmetry visually in order to explore publication bias. If there is a suspicion of publication bias, we will carry out a simulation to investigate the possible small-study effect. Heterogeneity will be assessed among included studies in each analysis using the chi-square test of heterogeneity and $I^2$ statistic. Data from each study will be pooled using random effects modeling where appropriate. To examine the robustness of results, we will perform meta-analyses using fixed-effect models after attributing less weight to small trials. We will use these meta-analyses only if their results differ from those of random effects models. When an $I^2$ score of $>75\%$ is obtained, we will consider heterogeneity to be substantial.

**Discussion**

To our knowledge, this will be the first meta-analysis to assess the association between physical performance and cardiovascular events in CAD patients. The main goals for CAD patients are to prevent re-admission due to cardiac events and improve mortality. Many cohort studies have demonstrated that physical performance testing is strongly associated with mortality and cardiac events for CAD patients. Furthermore, physical performance testing is a quick, safe, inexpensive, and reliable assessment tool. We hope that our findings may help to estimate the prognosis for CAD patients in clinical practice.

**Appendix**

**Search strategies**

A. EMBASE

1. Exp Heart Failure/OR Exp Ischemic Heart Disease/OR Exp Cardiomegaly/OR Exp Cardiomyopathy/OR Exp Coronary Artery Disease/OR Coronary Artery Bypass Graft/OR Exp Coronary Blood vessel/OR Exp Heart Surgery/OR Exp Percutaneous Coronary Intervention/OR (Myocardial Ischemia$ OR Myocardial Infarct$ OR Cardiovascular Stroke OR Ischemic Heart Disease$ OR Angina$ OR ((Heart OR Cardiac OR Myocardial) adj2 (Failure$ OR Surg$ OR Operat$ OR Resect$ OR Transplant$ OR Graft$ OR Massage$))) OR CHF OR CABG OR Coronary OR Aortocoronary OR Sinus Node Arter$ OR Intracardiac Surg$ OR Cardiosurg$ OR Annu loplast$ OR Valve Annu$l$ OR Cardiomyoplast$ OR Cardioplegia$ OR Heart Bypass$ OR Ventric$ Bypass$ OR Cavopulmonary Anastomos$ OR Cavopulmonary Shunt$ OR Heart Valv$ OR Cardiac Valv$ OR Aort$ Valv$ OR Mitral Valv$ OR Pulmonary Valv$ OR Tricuspid Valv$ OR ((Heart OR Myocardial OR Trans myocardial OR Trans Myocardial) adj2 Revascular$) OR Internal Mammary Artery Implant$ OR Percardiostom$ OR Percardiotom$ OR Percardiotom$ OR Perci diences$ OR Percardial Aspirat$ OR Percardium Puncture$ OR Rotational Atherectomy$ OR Epicard$ Mapping OR Heart Aneurysmectomy$ OR Valvuloplast$ OR Valv$ Repair$ OR Valvotomy$ OR Valvulotom$ OR ((Prosthe$ OR Artificial OR Mechanical) adj2 Valve$) OR Heart Enlargement$ OR Enlarged Heart OR Cardiac Hypertroph$ OR Heart Hyper troph$ OR Cardiomyopath$ OR Ventric$ Hypertroph$ OR Atrial Dilatation OR Atrial Enlargment OR Atrial Hypertroph$ OR Atriomegaly OR Atrium Dilatation OR Atrium Enlargement OR Atrium Hypertroph$ OR Cardiac Muscle Hypertroph$ OR Heart Hyperplasia OR Heart Muscle Hypertroph$ OR Myocardical Hypertroph$ OR Myocardial Hypertroph$ OR Ventric$ Wall Thickness OR Myocardial Disease$ OR Myocardio$ OR Adhali$ OR Antopol Disease OR Ventric$ Dysplasia OR Trypanosomiasis OR Carditis OR Endocardial Fibroelastos$ OR Endomyocardial Fibro lastosis OR Endomyocardial Fibros$ OR Myocardial Ischemic Reperfusion Injur$ OR Myocarditi$ OR Obstructive Asymmetric Septal Hypertroph$ OR Heart Amyloidosis OR Heart Myopath$ OR Cardiac Amyloidosis OR Oculocraniosomat$.ti,ab.

2. Exp Leg/OR Exp Arm/AND (Strength OR Force).ti,ab.

3. Exp Walking/ OR Muscle Strength/OR (Postural Balance OR Musculoskeletal Equilibrium OR Postural Equilibrium OR Gait OR Gaits OR Stair$ Navigation$ OR ((Hand OR Hands OR Pinch OR Leg OR Legs OR Lower Extremi$ OR Lower Limb$ OR Membrum Inferius OR Upper Extremi$ OR Upper Limb$ OR Membrum Superius OR Muscle$ OR Muscle? Dynamic OR Muscular OR Muscular Dynamic OR Arm OR Arms) adj (Strength OR Force OR Power)) OR Grip OR Grasp OR Walk$ OR Locomotion OR Ambulation OR (Physical adj (Balance OR Function OR Performance OR Strength OR Activit$))).ti,ab.

4. 2 OR 3

5. Exp cohort analysis/OR Exp longitudinal study/OR Exp prospective study/OR Exp follow up/OR Cohort$.tw.

6. 1 AND 4 AND 5

7. limit 6 to human

8. limit 7 to exclude medline journals

B. MEDLINE

1. Exp Heart Failure/OR Exp Myocardial Ischemia/OR Exp Cardiomegaly/OR Exp Cardiomyopathies/OR Exp Coronary Disease/OR Exp Coronary Artery Bypass/OR Exp Coronary Vessels/OR Exp Cardiac...
Surgical Procedures/OR Exp Percutaneous Coronary Intervention/OR (Myocardial Ischemia OR Myocardial Infarction) OR Cardiovascular Stroke? OR Ischemic Heart Disease? OR Angina? OR ((Heart OR Cardiac OR Myocardial) adj2 (Failure? OR Surg OR Operat? OR Resect? OR Transplant? OR Graft?) OR (Myocarditis OR "Heart Myocarditis" OR "Myocardial Ischemic Reperfusion Injury" OR "Endomyocardial Fibrosis" OR "Myocardial Ischemic Reperfusion Injury" OR "Endomyocardial Fibroelastosis" OR "Endomyocardial Fibrosis" OR "Myocardial Ischemia OR Myocardial Infarction") OR (Heart OR Myocardial OR Transplantation? OR "Heart Enlargement"? OR "Enlarged Heart" OR "Cardiac Hypertrophy" OR "Heart Hypertrophy" OR "Cardiomyopathy" OR "Atrial Hypertrophy" OR "Heart Muscle Hypertrophy" OR "Myocardium Hypertrophy" OR "Ventricular Hypertrophy" OR "Cardiomyopathy OR Atrial Dilatation OR Atrial Enlargement OR Cardiac Hypertrophy OR "Atrial Hypertrophy" OR "Heart Muscle Hypertrophy" OR "Myocardium Hypertrophy" OR "Myocardial Disease? OR "Myocardiopathy" OR Adhalinopathy OR Sarcoglycanopathy OR Antopol Disease OR Venticular Hypertrophy OR Dysplasia OR "Trypanosomiasis OR Carditis OR Endocardial Fibroelastosis? OR Endomyocardial Fibroelastosis OR "Endomyocardial Fibrosis" OR "Myocardial Ischemic Reperfusion Injury" OR "Myocarditis" OR Obstructive Asymmetric Septal Hypertrophy OR "Heart Amyloidosis" OR "Cardiac Amyloidosis OR Oculocranial somatic).ti,ab.

2. Exp Lower Extremity/OR Exp Upper Extremity/ AND (Strength OR Force OR Power).ti,ab.

3. Postural Balance/OR Gait/OR Exp Muscle Strength/OR Muscle Strength Dynamometer/OR Exp Walking/OR (Postural Balance OR Musculoskeletal Equilibrium OR Postural Equilibrium OR Gait OR Gaits OR Stair? Navigation? OR ((Hand OR Hands OR Pinch OR Leg OR Legs OR Lower Extremity OR Lower Limb? OR Membrum Inferius OR Upper Extremity OR Upper Limb? OR Membrum Superius OR Muscle? OR Muscle? Dynamic OR Muscular OR Muscular Dynamic OR Arm OR Arms) adj (Strength OR Force OR Power)) OR Grip OR Grips OR Grasp? OR Walk$ OR Locomotion OR Ambulation OR (Physical adj (Balance OR Function OR Performance OR Strength OR Activiti$)).ti,ab.

4. 2 OR 3

5. Exp cohort studies/ or Cohort$.tw. or Controlled clinical trial.pt.

6. Epidemiologic methods/

7. Limit 2 to yr = 1971-1988

8. 5 OR 7

9. 1 and 4 and 8

10. limit 9 to humans

C. PubMed

("Myocardial Ischemia"[tiab] OR "Myocardial Infarction"[tiab] OR "Cardiovascular Stroke"[tiab] OR "Cardiovascular Disease"[tiab] OR "Cardiovascular Events"[tiab] OR "Ischemic Heart Disease"[tiab] OR Angina OR ((Heart OR Cardiac OR Myocardial) AND (Heart OR Myocardial OR Transplantation? OR Heart OR "Heart Enlargement" OR "Enlarged Heart" OR "Cardiac Hypertrophy" OR "Heart Hypertrophy" OR "Cardiomyopathy" OR "Atrial Hypertrophy" OR "Heart Muscle Hypertrophy" OR "Myocardium Hypertrophy" OR "Ventricular Hypertrophy" OR "Cardiomyopathy OR Atrial Dilatation OR Atrial Enlargement OR Cardiac Hypertrophy OR "Atrial Hypertrophy" OR "Heart Muscle Hypertrophy" OR "Myocardium Hypertrophy" OR "Myocardial Disease? OR "Myocardiopathy" OR Adhalinopathy OR Sarcoglycanopathy OR Antopol Disease OR "Ventricular Hypertrophy" OR "Dysplasia OR "Trypanosomiasis OR Carditis OR Endocardial Fibroelastosis? OR Endomyocardial Fibroelastosis OR "Endomyocardial Fibrosis" OR "Myocardial Ischemic Reperfusion Injury" OR "Myocarditis" OR Obstructive Asymmetric Septal Hypertrophy OR "Heart Amyloidosis" OR "Cardiac Amyloidosis OR Oculocranial somatic).ti,ab.
AND Limb*[tiab]) OR (Upper*[tiab] AND EXTremity*[tiab])
OR (Upper*[tiab] AND Limb*[tiab]) OR Muscle*[tiab] OR (Muscle*[tiab] AND Dynamic*[tiab]) OR Muscular*[tiab]
OR Arm*[tiab] OR Arms*[tiab]) AND (Strength*[tiab] OR Force*[tiab] OR Power*[tiab]) OR Grip*[tiab] OR Grips*[tiab]
OR Grasp*[tiab] OR Walk*[tiab] OR Locomotion*[tiab] OR Ambulation*[tiab] OR (Physical*[tiab] AND (Balance*[tiab]
OR Function*[tiab]) OR Performance*[tiab] OR STrength*[tiab] OR Activit*[tiab]))) AND ("Cohort Studies"[MeSH] OR Cohort*[All Fields] OR "Controlled Clinical Trial"[pt] OR Prospective*[tiab] OR Follow-Up*[tiab] OR "Follow Up"[tiab]
OR Followup*[tiab]) NOT MEDLINE[sb]
D. Cochrane Library
#1 MeSH descriptor: [Heart Failure] explode all trees
#2 MeSH descriptor: [Myocardial Ischemia] explode all trees
#3 MeSH descriptor: [Cardiomegaly] explode all trees
#4 MeSH descriptor: [Cardiomyopathies] explode all trees
#5 MeSH descriptor: [Coronary Disease] explode all trees
#6 MeSH descriptor: [Coronary Artery Bypass] explode all trees
#7 MeSH descriptor: [Coronary Vessels] explode all trees
#8 MeSH descriptor: [Cardiac Surgical Procedures] explode all trees
#9 MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees
#10 (Myocardial Ischemia* or Myocardial Infarct* or Cardiovascular Stroke* or Ischemic Heart Disease* or Angina* or ((Heart or Cardiac or Myocardial) near/2 (Failure* or Surg* or Operat* or Resec* or Transplant* or Graft* or Massage*)) or CHF or CABG or Coronary or Aortocoronary or Sinus Node Arter* or Intracardiac Surg* or Cardiosurg* or Annuloplast* or Valve Annul* or Cardiomyoplast* or Cardioplegia* or Heart Bypass* or Ventric* Bypass* or Cavopulmonary Anastomos* or Cavopulmonary Shunt* or Heart Valv* or Cardiac Valv* or Aort* Valv* or Mitral Valv* or Pulmonary Valv* or Tricuspid Valv* or ((Heart or Myocardial or Transmyocardial or Trans Myocardial) near/2 Revasculari*) OR Internal Mammary Artery Implant* or Pericardiotom* or Pericardiotomy* or Pericardiectomy* or Pericardiotomy* or Pericardiotom* or Pericardioentesis* or Pericardial Aspirat* or Pericardium Puncture* or Rotational Atherectomy* or Epicard* Mapping or Heart Aneurysmectomy* or Valvuloplast* or Valv* Repair* or Valvotom* or Valvulotomy* or ((Prosth* or Artificial or Mechanical) near/2 Valve*) or Heart Enlargement* or Enlarged Heart or Cardiac Hypertroph* or Heart Hypertroph* or Cardiomyopath* or Ventric* Hypertroph* or Atrial Dilatation or Atrial Enlargement or Atrial Hypertroph* or Atriumegaly or Atrium Dilatation or Atrium Enlargement or Atrium Hypertroph* or Cardiac Muscle Hypertroph* or Heart Hyperplasia or Heart Muscle Hypertroph* or Myocardial Hypertroph* or Myocardium Hypertroph* or Ventric* Wall Thickness or Myocardial Disease* or Myocardio-path* or Adhalinopath* or Sarcoglycanopath* or Antopol Disease or Ventric* Dysplasia or Trypanosomiasis or Carditis or Endocardial Fibroelastosis* or Endomyocardial Fibrosis* or Myocardial Ischemic Reperfusion Injury* or Myocardit* or Obstructive Asymmetric Septal Hypertroph* or Heart Amyloidosis or Heart Myopathy* or Cardiac Amyloidosis or Oculocraniosomatic):ti,ab
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Lower Extremity] explode all trees
#13 MeSH descriptor: [Upper Extremity] explode all trees
#14 (Strength or Force or Power):ti,ab
#15 MeSH descriptor: [Postural Balance] explode all trees
#16 MeSH descriptor: [Gait] explode all trees
#17 MeSH descriptor: [Muscle Strength] explode all trees
#18 MeSH descriptor: [Muscle Strength Dynamometer] explode all trees
#19 MeSH descriptor: [Walking] explode all trees
#20 (Postural Balance or Musculoskeletal Equilibrium or Postural Equilibrium or Gait or Gaits or Stair* Navigation or ((Hand or Hands or Pinch or Leg or Legs or Lower Extremity* or Lower Limb* or Membrum Inferius or Upper Extremity* or Upper Limb* or Membrum Superius or Muscle* or Muscle* Dynamic or Muscular or Muscular Dynamic or Arm or Arms) near/1 (Strength or Force or Power)) or Grip or Grips or Grasp* or Walk* or Locomotion or Ambulation or (Physical near/1 (Balance or Function or Performance or Strength or Activit*)):ti,ab
#21 (Heart Failure or Myocardial Ischemia or Myocardial Infarct or Cardiovascular Stroke or Ischemic Heart Disease or Angina or ((Heart or Cardiac or Myocardial) near/2 (Failure or Surg or Operat or Resec or Transplant or Graft or Massage)) or CHF or CABG or Coronary or Aortocoronary or Sinus Node Arter or Intracardiac Surg or Cardiosurg or Annuloplast or Valve Annul or Cardiomyoplast or Cardioplegia or Heart Bypass or Ventric Bypass or Cavopulmonary Anastomos or Cavopulmonary Shunt or Heart Valv or Cardiac Valv or Aort Valv or Mitral Valv or Pulmonary Valv or Tricuspid Valv or ((Heart or Myocardial or Transmyocardial or Trans Myocardial) near/2 Revasculari) or Internal Mammary Artery Implant or Pericardiotom or Pericardiotomy or Pericardiotectomy or Pericardiotomy or Pericardiotom or Pericardioentesis or Pericardial Aspirat or Pericardium Puncture or Rotational Atherectomy or Epicard Mapping or Heart Aneurysmectomy or Valvuloplast or Valv Repair or Valvotom or Valvulotomy or ((Prosth or Artificial or Mechanical) near/2 Valve) or Heart Enlargement or Enlarged Heart or Cardiac Hypertroph or Heart Hypertroph or Cardiomyopath or Ventric Hypertroph or Atrial Dilatation or Atrial Enlargement or Atrial Hypertroph or Atriumegaly or Atrium Dilatation or Atrium Enlargement or Atrium Hypertroph or Cardiac Muscle Hypertroph or Heart Hyperplasia or Heart Muscle Hypertroph or Myocardial Hypertroph or Myocardium Hypertroph or Ventric Wall Thickness or Myocardial Disease or Myocardio-path or Adhalinopath or Sarcoglycanopath or Antopol Disease or Ventric Dysplasia or Trypanosomiasis or Carditis or Endocardial Fibroelastosis or Endomyocardial Fibrosis or Myocardial Ischemic Reperfusion Injury or Myocardit or Obstructive Asymmetric Septal Hypertroph or Heart Amyloidosis or Heart Myopathy or Cardiac Amyloidosis or Oculocraniosomatic):ti,ab
#22 #12 or #13 and #14
#22 #15 or #16 or #17 or #18 or #19 or #20 or #21 #23 #11 and #22

Abbreviations
ACROBAT-NRSI: A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions; CAD: coronary artery disease; MOOSE: Meta-analysis of Observational Studies in Epidemiology.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SY conceived of the study and drafted the manuscript. TI and SN helped to revise the manuscript. MO and YS provided the statistical advice. TY and EO participated in the design of the study and revised the manuscript. RM conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Ms. Emma Barber for her editorial support. We also thank the Trial Search Coordinator of the Cochrane Schizophrenia Group for their support on the search strategy.

Funding
This research was supported by a Grant from the National Center for Child Health and Development, Tokyo, Japan (26-5).

Author details
1Department of Rehabilitation, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto-shi, Nagano 390-8621, Japan. 2Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan. 3Department of Physical Therapy, School of Health Sciences, Shinshu University, Nagano, Japan.

Received: 3 October 2015 Accepted: 8 February 2016

References
1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.
2. Oremus M, Don-Wauchope A, McKelvie R, Santaguida PL, Hill S, Balion C, et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev. 2014;19(4):471–505.
3. Goto T, Wakami K, Fukuta H, Fujita H, Tani T, Ohbe N. Patients with left ventricular ejection fraction greater than 58 % have fewer incidences of future acute decompensated heart failure admission and all-cause mortality. Heart Vessels. 2015. doi:10.1007/s00380-015-0657-1.
4. Shiba N, Shimokawa H. Chronic heart failure in Japan: implications of the CHART studies. Vasc Health Risk Manag. 2008;4(1):103–13.
5. Yamamoto S, Matsunaga A, Wang G, Hoshi K, Kamiya K, Noda C, et al. Effect of balance training on walking speed and cardiac events in elderly patients with ischemic heart disease. Int Heart J. 2014;55(5):397–403.
6. Kamiya K, Masuda T, Tanaka S, Hamazaki N, Matsue Y, Mezzani A, et al. Quadriceps strength as a predictor of mortality in coronary artery disease. Am J Med. 2015;128(11):1212–9.
7. Yamamoto S, Matsunaga A, Kamiya K, Mida K, Ebina Y, Hotta K, et al. Walking speed in patients with first acute myocardial infarction who participated in a supervised cardiac rehabilitation program after coronary intervention. Int Heart J. 2012;53(2):347–52.
8. Chiariotti D, Volpato S, Sioulis F, Bartalucci F, Del Bianco L, Mangani L, et al. Lower extremity performance measures predict long-term prognosis in older patients hospitalized for heart failure. J Card Fail. 2010;16(5):390–5.
9. Zaharias E, Cataldo J, Mackin L, Howie-Esquibel J. Simple measures of function and symptoms in hospitalized heart failure patients predict short-term cardiac event-free survival. Nurs Res Pract. 2014;2014:815984.
10. Sanchis J, Bonanad C, Ruiz V, Fernandez J, Garcia-Blas S, Mainar L, et al. Frailty and other geriatric conditions for risk stratification of older patients with acute coronary syndrome. Am Heart J. 2014;168(5):784–91, e2.
11. Izawa KP, Watanabe S, Osada N, Kasahara Y, Yokoyama H, Hiraki K, et al. Handgrip strength as a predictor of prognosis in Japanese patients with congestive heart failure. Eur J Cardiovasc Prev Rehabil. 2009;16(1):21–7.
12. Huismann M, Quittan M, Berger R, Crevenna R, Springer C, Nuhr M, et al. Muscle strength as a predictor of long-term survival in severe congestive heart failure. Eur J Heart Fail. 2004;6(1):101–7.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):1858–64.
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7), e1000097.
15. Shamseer L, Moher D, Clarke M, Gherezi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
16. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66(4):408–14.
17. Higgins JPT, S G. Cochrane handbook for systematic reviews of interventions. England: The Cochrane collaboration; 2012.